E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis.

Amino Acid Substitution Cell Line, Tumor GTP Phosphohydrolases / genetics HEK293 Cells Humans MAP Kinase Signaling System Melanoma / genetics Membrane Proteins / genetics Mutation, Missense Proto-Oncogene Proteins B-raf / genetics Ubiquitin-Protein Ligases / genetics ets-Domain Protein Elk-1 / genetics
ChIP ERK MAPK chromatin immunoprecipitation extracellular signal-regulated kinase gene regulation melanoma mitogen-activated protein kinase parkin transcription factor tumor suppressor gene

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
20 11 2020
Historique:
received: 29 05 2020
revised: 09 09 2020
pubmed: 18 9 2020
medline: 10 3 2021
entrez: 17 9 2020
Statut: ppublish

Résumé

Malignant melanoma, the most aggressive form of skin cancer, is characterized by high prevalence of

Identifiants

DOI: 10.1074/jbc.RA120.014615 PMID: 32938713 PMC: PMC7681032
pubmed: 32938713
pii: S0021-9258(17)50431-7
doi: 10.1074/jbc.RA120.014615
pmc: PMC7681032
pii:
doi:

Substances chimiques

ELK1 protein, human 0
Membrane Proteins 0
ets-Domain Protein Elk-1 0
Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
GTP Phosphohydrolases EC 3.6.1.-
NRAS protein, human EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16058-16071

Informations de copyright

© 2020 Montagnani et al.

Déclaration de conflit d'intérêts

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Références

Nat Commun. 2017 Nov 28;8(1):1823
pubmed: 29180628
Mol Cell. 2013 Jun 27;50(6):844-55
pubmed: 23727019
PLoS Comput Biol. 2014 Nov 06;10(11):e1003935
pubmed: 25375667
Cell Cycle. 2013 Apr 1;12(7):1133-41
pubmed: 23470638
N Engl J Med. 2000 May 25;342(21):1560-7
pubmed: 10824074
J Genet Genomics. 2016 Jun 20;43(6):369-79
pubmed: 27297116
Nature. 1998 Apr 9;392(6676):605-8
pubmed: 9560156
Genome Res. 2009 Nov;19(11):1963-73
pubmed: 19687146
Nat Genet. 2014 Jun;46(6):588-94
pubmed: 24793136
Cell. 1993 Apr 23;73(2):381-93
pubmed: 8386592
Stem Cells. 2012 Sep;30(9):1808-18
pubmed: 22730244
Neoplasia. 2017 Feb;19(2):75-83
pubmed: 28038320
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
J Mol Med (Berl). 2014 Jan;92(1):31-42
pubmed: 24297497
Cancer Res. 2012 May 15;72(10):2543-53
pubmed: 22431710
Nature. 2009 May 28;459(7246):569-73
pubmed: 19404257
Front Oncol. 2019 Aug 23;9:790
pubmed: 31508359
Brain. 2003 Jun;126(Pt 6):1271-8
pubmed: 12764050
Dev Cell. 2018 Aug 20;46(4):441-455.e8
pubmed: 30100261
J Biol Chem. 2010 Sep 17;285(38):29231-8
pubmed: 20630868
Oncotarget. 2015 Dec 15;6(40):42704-16
pubmed: 26516701
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37
pubmed: 11715049
Clin Cancer Res. 2005 Oct 15;11(20):7234-42
pubmed: 16243793
PLoS Genet. 2012;8(5):e1002694
pubmed: 22589737
Cell Death Dis. 2018 Mar 7;9(3):375
pubmed: 29515107
Cell Rep. 2014 Nov 20;9(4):1538-53
pubmed: 25456142
Nat Cell Biol. 2006 Aug;8(8):834-42
pubmed: 16862145
Oncotarget. 2016 May 24;7(21):30365-78
pubmed: 27095580
J Transl Med. 2010 Apr 20;8:39
pubmed: 20406486
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Science. 2016 Oct 14;354(6309):233-237
pubmed: 27738173
Cell Death Differ. 2015 Dec;22(12):2006-19
pubmed: 26024388
Neurol Genet. 2016 Apr 13;2(3):e70
pubmed: 27123489
Pharmacol Res. 2012 Aug;66(2):105-43
pubmed: 22569528
Front Neurosci. 2011 Mar 16;5:35
pubmed: 21441990
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
EMBO J. 1995 Mar 1;14(5):951-62
pubmed: 7889942
Cell. 1993 Aug 27;74(4):609-19
pubmed: 8358790
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15145-50
pubmed: 20696900
Cell Death Dis. 2018 Feb 2;9(2):142
pubmed: 29396391
Cancer Lett. 2018 Oct 1;433:156-164
pubmed: 29981809
Nat Genet. 2010 Jan;42(1):77-82
pubmed: 19946270
J Natl Cancer Inst. 2015 Dec 17;108(3):
pubmed: 26683220
Oncogene. 2017 Jun 8;36(23):3322-3333
pubmed: 28068326
Cancer Res. 2015 May 1;75(9):1815-27
pubmed: 25877876
Cancer Discov. 2013 Jul;3(7):742-50
pubmed: 23614898
Hum Mol Genet. 2009 Sep 1;18(17):3206-16
pubmed: 19483198
Mol Cell. 2017 Mar 16;65(6):999-1013.e7
pubmed: 28306514
Biochem Soc Trans. 2015 Apr;43(2):269-74
pubmed: 25849928
Clin Cancer Res. 2004 Apr 15;10(8):2720-4
pubmed: 15102676

Auteurs

Valentina Montagnani (V)

Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Luisa Maresca (L)

Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Alessandro Apollo (A)

Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.

Sara Pepe (S)

Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy; Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Ryan M Carr (RM)

Division of Oncology Research, Department of Oncology, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota USA.

Martin E Fernandez-Zapico (ME)

Division of Oncology Research, Department of Oncology, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota USA.

Barbara Stecca (B)

Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. Electronic address: b.stecca@ispro.toscana.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Substitution d'acide aminé › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Acid anhydride hydrolases › dGTPases › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Système de signalisation des MAP kinases › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutation faux-sens › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-protein ligases › E3 ubiquitin ligase PARK2, an inhibitor of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines proto-oncogènes c-ets › Facteurs du complexe ternaire › Protéine Elk-1 à domaine ets › E3 ubiquitin ligase PARK2, an inhibitor of...